Aviance Capital Partners LLC continued to hold its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Aviance Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $1,473,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Korea Investment CORP increased its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $140,000. Alpha Windward LLC increased its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Wendell David Associates Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $204,000. Finally, Welch & Forbes LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at $211,000. Hedge funds and other institutional investors own 66.70% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 0.09% during trading on Tuesday, hitting $469.68. The stock had a trading volume of 484,690 shares. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The firm’s 50-day moving average is $499.39 and its 200-day moving average is $422.69. The firm has a market cap of $49.58 billion, a P/E ratio of 56.86 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period last year, the firm posted $2.82 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.83 EPS for the current year.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Position Maintained by Aviance Capital Partners LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/08/aviance-capital-partners-llc-has-1473000-stake-in-regeneron-pharmaceuticals-inc-regn-updated.html.

Several equities research analysts have weighed in on the company. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target on the stock. in a report on Tuesday. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, August 3rd. Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Citigroup Inc. upped their price target on Regeneron Pharmaceuticals to $575.00 and gave the stock a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $477.91.

In other news, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $1,350,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Sanofi purchased 136,050 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, June 2nd. The shares were purchased at an average cost of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 59,396 shares of company stock worth $28,484,734. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.